Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
Cell Rep. 2019 Jan 22;26(4):955-968.e3. doi: 10.1016/j.celrep.2018.12.102.
Alternative lengthening of telomeres (ALT) is a telomerase-independent but recombination-dependent pathway that maintains telomeres. Here, we describe an assay to visualize ALT-mediated telomeric DNA synthesis in ALT-associated PML bodies (APBs) without DNA-damaging agents or replication inhibitors. Using this assay, we find that ALT occurs through two distinct mechanisms. One of the ALT mechanisms requires RAD52, a protein implicated in break-induced DNA replication (BIR). We demonstrate that RAD52 directly promotes telomeric D-loop formation in vitro and is required for maintaining telomeres in ALT-positive cells. Unexpectedly, however, RAD52 is dispensable for C-circle formation, a hallmark of ALT. In RAD52-knockout ALT cells, C-circle formation and RAD52-independent ALT DNA synthesis gradually increase as telomeres are shortened, and these activities are dependent on BLM and BIR proteins POLD3 and POLD4. These results suggest that ALT occurs through a RAD52-dependent and a RAD52-independent BIR pathway, revealing the bifurcated framework and dynamic nature of this process.
端粒的非经典延长(ALT)是一种端粒酶独立但依赖重组的途径,可维持端粒。在这里,我们描述了一种在没有 DNA 损伤剂或复制抑制剂的情况下可视化 ALT 相关 PML 体(APB)中 ALT 介导的端粒 DNA 合成的测定方法。使用该测定方法,我们发现 ALT 发生通过两种不同的机制。其中一种 ALT 机制需要 RAD52,这是一种与断裂诱导的 DNA 复制(BIR)有关的蛋白质。我们证明 RAD52 可直接促进体外端粒 D 环形成,并且是维持 ALT 阳性细胞中端粒所必需的。然而,出乎意料的是,RAD52 对于 C 环形成(ALT 的标志)是可有可无的。在 RAD52 敲除的 ALT 细胞中,随着端粒缩短,C 环形成和 RAD52 非依赖的 ALT DNA 合成逐渐增加,这些活性依赖于 BLM 和 BIR 蛋白 POLD3 和 POLD4。这些结果表明,ALT 通过依赖 RAD52 和非依赖 RAD52 的 BIR 途径发生,揭示了该过程的分支框架和动态性质。
Nucleic Acids Res. 2020-2-20
Nat Struct Mol Biol. 2025-8-22
J Transl Med. 2025-8-14
Nucleic Acids Res. 2025-8-11
Chromosome Res. 2025-8-4
Nat Commun. 2025-7-11
MedComm (2020). 2025-7-1
Cell Biosci. 2025-3-1